Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Reprogenetics, the largest genetics laboratory in the United States specializing in Preimplantation Genetic Screening (PGS), the technique of examining the normal number of chromosomes in embryos, announced the grand opening of its new facility in Miami, Florida.
Subscribe to our email newsletter
Reprogenetics will announce this to clients at the Florida Society of Reproductive Endocrinology and Infertility Meeting (FSREI), Saturday, August 16 at The Ritz-Carlton in Orlando. Rounding out its full access to patients across the country with locations in New Jersey — where it is headquartered — and Chicago, Los Angeles and Oregon, Reprogenetics is committed to patients and improving their chances for positive pregnancy outcomes, with this southeast facility focusing specifically on chromosome testing to identify embryo abnormalities.
"We’re excited to expand our offerings to better serve patients in the southeast, addressing the growing need for reproductive genetic testing to lead to healthy baby births," said Santiago Munné, MD, Founder and Director, Reprogenetics. "We are also pleased to announce the promotion of our Preimplantation Genetic Diagnosis (PGD) specialist Renata Prates, who has relocated from our New Jersey site to operate as the Lab Director. She brings years of experience, education and multilingual capabilities, all which make her an ideal leader for our new facility."
"I’m honored to be chosen to head the Reprogenetics laboratory in Miami to provide patients in the southeast area access to valuable science and technology that can improve their positive pregnancy outcomes," says Renata Prates, Reprogenetics Miami Lab Director. "With the goal to collaborate with researchers to support patient needs in this market, we are pleased to share that our first procedure is well underway. I hope to meet you in person at the FSREI meeting at vendor booth number 106."
Reprogenetics maintains a strong focus on technology, research and development, creating literature in well over 300 publications while staying at the forefront of research contributing to the majority of technologies now used in PGD laboratories. The company spends nearly one quarter of revenue on studies and research related to developing new technologies and enhancing existing ones. Reprogenetics is currently collaborating with more than 20 institutes to improve the future of PGD.